Subin Baral

Subin Baral
Subin Baral, EY Global Life Sciences Deals Leader Subin is a partner at Ernst & Young LLP, and the Global Life Sciences Deals Leader. He has more than a decade of transaction experience, helping life sciences companies on transformational transactions. He has extensive global experience serving as a sell-side transaction advisor for Fortune 500 companies, including corporate and private equity. His experience includes working with companies in the pharmaceutical, medical device and biotechnology subsectors. Subin focuses on acquisitions, carve-outs, spin-offs and initial public offerings and works with companies at all stages of maturity, from start-up to public company. He frequently …
Subin Baral, EY Global Life Sciences Deals Leader

Subin is a partner at Ernst & Young LLP, and the Global Life Sciences Deals Leader. He has more than a decade of transaction experience, helping life sciences companies on transformational transactions. He has extensive global experience serving as a sell-side transaction advisor for Fortune 500 companies, including corporate and private equity. His experience includes working with companies in the pharmaceutical, medical device and biotechnology subsectors.

Subin focuses on acquisitions, carve-outs, spin-offs and initial public offerings and works with companies at all stages of maturity, from start-up to public company. He frequently speaks at life sciences events on acquisitions and divestitures topics.

He received his Master of Commerce from Macquarie University, Sydney, Australia. He is a chartered accountant from the Institute of Chartered Accountants of Australia and New Zealand.
See more

Articles: Subin Baral

Transact to Transform: How can Biopharmas use Alliances & Partnerships to Drive Innovation?

Global / Drawing on the findings of EY’s recently published life sciences M&A firepower report, EY Global Life Sciences Deals Leader Subin Baral makes the case for big biopharmas to seek out alliances and partnerships as an alternative to M&A and lists ten considerations that these firms should bear in mind if they want to use strategic…

See more